What is FRC's Proprietary Fair Value Model?

FRC's Proprietary Fair Value Model is a premium feature built on Fundamental Research Corp's institutional-grade valuation methodology. This institutional-grade model combines fundamental analysis, financial modeling, and market metrics to determine a stock's intrinsic value. The model analyzes financial statements, earnings quality, growth rates, profitability ratios, and comparative valuations to calculate data-driven fair value estimates that professional investors trust for investment decisions. Available to premium subscribers.

What is NurExone Biologic Inc. stock price today?

NurExone Biologic Inc. (NRX.V) is currently trading at $0.47 CAD on TSXV. Get real-time price updates, Snowflake performance analysis, and comprehensive financial statements. Premium subscribers can access fair value analysis using FRC's proprietary valuation model.

What does NurExone Biologic Inc. do?

NurExone Biologic Inc. operates in the Biotechnology sector within Healthcare. NurExone Biologic Inc., a pharmaceutical technology company, develops a platform for biologically guided exosome-based therapies for the treatment of central nervous system injuries. Its lead product,...

How do I analyze NurExone Biologic Inc. stock performance?

Our Snowflake Analysis provides a visual snapshot of NurExone Biologic Inc. performance across 5 key metrics: Past Performance, Revenue Growth, Profitability, Value, and Financial Health. Each metric is scored 1-5, with 5 being excellent performance. This multi-dimensional view helps investors quickly assess stock quality and compare performance against peers.

Where can I find NurExone Biologic Inc. financial statements?

Access NurExone Biologic Inc. complete financial statements including income statement, balance sheet, and cash flow statement in our comprehensive stock profile. Our platform provides detailed financial ratios, trend analysis, and institutional-grade financial analysis used by professional investors.

What makes FRC's stock analysis different from other platforms?

FRC applies its proprietary valuation model to public stock analysis, so fair value estimates rest on a rigorous, data-driven methodology rather than a consensus average. Our analysis includes real-time pricing, Snowflake performance metrics, comprehensive financial modeling, and research reports from professional analysts - providing institutional-grade insights for individual investors.

About NurExone Biologic Inc.

Industry

Biotechnology

Sector

Healthcare

CEO

Dr. Lior Shaltiel

Headquarters

1 First Canadian Place Suite 1600 100 King Street West, Toronto, ON, CA

Industry

Biotechnology

Sector

Healthcare

CEO

Dr. Lior Shaltiel

Headquarters

1 First Canadian Place Suite 1600 100 King Street West, Toronto, ON, CA

Description

NurExone Biologic Inc., operates as a pharmaceutical technology company. It is developing an off-the-shelf, non-invasive, and novel treatment for the reversal or reduction of paralysis following spinal cord injury using membrane-bound extracellular vesicles technology, as well as to treat brain trauma injury, and other brain and neurological indications. The company was founded in 2020 and is based in Toronto, Canada.

NurExone Biologic Inc.

FRC Coverage

NRX.V•TSXV

NurExone Biologic Inc.

FRC Coverage

NRX.V•TSXV

Sentiment

Your view on NRX.V

Sentiment

Your view

Company Overview

Overview

What the company does, where it operates, and who runs it.

*NurExone Biologic Inc. has paid FRC a fee for research coverage and distribution of reports.

About NurExone Biologic Inc.

Industry: Biotechnology
Sector: Healthcare
CEO: Dr. Lior Shaltiel
Headquarters: 1 First Canadian Place Suite 1600 100 King Street West, Toronto, ON, CA

Industry: Biotechnology
Sector: Healthcare
CEO: Dr. Lior Shaltiel
Headquarters: 1 First Canadian Place Suite 1600 100 King Street West, Toronto, ON, CA

Description

FRC Research

Buy

Fair Value Estimate

CAD$2.00

A Potential Breakthrough in Spinal Cord and Optic Nerve Injury Treatment

Report · Dec 16, 2024

FRC Research

Buy

Fair Value Estimate

CAD$2.00

A Potential Breakthrough in Spinal Cord and Optic Nerve Injury Treatment

Report · Dec 16, 2024

FRC Research

Research Reports

FRC analyst coverage and recommendations.

Research Reports

1 report

*NurExone Biologic Inc. has paid FRC a fee for research coverage and distribution of reports.

Dec 16, 2024

A Potential Breakthrough in Spinal Cord and Optic Nerve Injury Treatment

NRX, an Israeli biotech company founded in 2020, is developing a novel drug delivery platform designed to provide minimally invasive

Past Reports

Historical coverage archive.

Analyst Notes

Ongoing commentary and updates from FRC analysts.

6 notes

*NurExone Biologic Inc. has paid FRC a fee for research coverage and distribution of reports.

Jul 21, 2025·1y agoLatest

Company Announcement

Preclinical study indicates significant improvement in walking quality in spinal cord injury model

FRC Analyst's Comment

Positive - NRX announced that animals treated with a higher dose of ExoPTEN showed significant recovery of motor function following spinal cord injury. Results demonstrated a clear dose-dependent improvement in mobility, and walking parameters, with no side effects observed at the higher dose. These promising preclinical findings support ExoPTEN’s potential as a treatment for acute spinal cord injury. NRX will continue optimizing dosing regimen, and manufacturing processes, while preparing for further studies, and regulatory engagement, with the goal of initiating first-in-human clinical trials.

Jul 21, 20251y agoLatest

Apr 28, 2025·1y ago

Company Announcement

Expands pipeline with promising preclinical results for facial nerve regeneratio

FRC Analyst's Comment

Positive - NurExone’s lead candidate, ExoPTEN, has demonstrated significant functional recovery and nerve regeneration in a preclinical model of facial nerve injury. These findings introduce a new potential therapeutic avenue for conditions such as Bell's palsy, Ramsay Hunt Syndrome, and other facial nerve disorders. This development marks NurExone’s third therapeutic focus, complementing its existing programs in spinal cord injury, and optic nerve regeneration. We believe NRX remains on track to initiate phase one clinical trials within the next 12 months.

Apr 28, 20251y ago

Apr 14, 2025·1y ago

Company Announcement

Announces U.S. uplisting intention, and closes $2.3M private placement

FRC Analyst's Comment

Positive - We believe NRX is on track to enter phase one clinical trials within 12 months. Last month, the company completed a preclinical study to support its application for an Investigational New Drug (IND) designation, a necessary step before initiating human clinical trials, for its ExoPTEN treatment for acute spinal cord injury (SCI). ExoPTEN has received orphan drug designation from the U.S. FDA, and the European Medicines Agency (EMA). We note that there is currently no cure for SCI.

Apr 14, 20251y ago

Media

Infographics, videos, and posts covering the company.

Financial Data

Stock Data

Price chart, volume, and trading data.

Fair Value

What FRC thinks the stock is worth vs. the current price.

FRC's fair value estimate for NurExone Biologic Inc., and the rating behind it. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

Valuation, profitability, liquidity and leverage ratios for NurExone Biologic Inc.. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

Dividend history, yield and payout sustainability for NurExone Biologic Inc.. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

Reported vs. expected earnings history for NurExone Biologic Inc.. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Financial Statements

Income statement, balance sheet, and cash flow statements.

Income statement, balance sheet and cash flow history for NurExone Biologic Inc.. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

NurExone Biologic Inc. valued side by side against its closest peers. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.

Ownership & News

Institutional Ownership

Which funds and firms own the stock.

Which institutions hold NurExone Biologic Inc., and how their positions are changing. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.

Insider Trading

Recent buying and selling by company executives.

Buying and selling by NurExone Biologic Inc. executives and directors. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.

Senate Trading

U.S. Senator disclosures filed under the STOCK Act.

U.S. Senate disclosures naming NurExone Biologic Inc.. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely.

House Trading

U.S. Representative disclosures filed under the STOCK Act.

U.S. House of Representatives disclosures naming NurExone Biologic Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals.

News

Latest headlines and market coverage.

Latest headlines and company announcements for NurExone Biologic Inc.. Press releases and market coverage, newest first.

News

Latest Market News